



MICROBIAL PROFILE AND ANTIBIOTIC SENSITIVITY IN PRETERM PREMATURE RUPTURE OF MEMBRANES (PPROM) AMONG PREGNANT WOMEN: IMPLICATIONS FOR TREATMENT IN RESOURCE-LIMITED SETTINGS

Anuradha V

Associate Professor, Department of Obstetrics & Gynecology, Sri Lakshmi Narayana Institute of Medical Sciences & Hospital, Osudu, Puducherry – 605502, India.

ABSTRACT

This study aimed to identify prevalent microbes in pregnant women with preterm premature rupture of membranes (PPROM) and assess their susceptibility to various antibiotics, with the goal of determining appropriate antibiotic treatment strategies in resource-limited settings. Endocervical swabs were collected from all participants, and microbiological examination was conducted to identify the prevalent microbes. Antibiotic susceptibility testing was performed using the Kirby-Bauer disk diffusion method. The results revealed that *Streptococcus* spp., *Staphylococcus aureus*, and *Escherichia coli* were significantly more prevalent in women with PPRM ($P < 0.01$). Among the tested antibiotics, cefixime, cefuroxime, and erythromycin demonstrated the highest sensitivity during pregnancy. Based on these findings, it is recommended that in the first 48 hours after the onset of PPRM in women, intravenous administration of antibiotics such as ampicillin-sulbactam, cefixime, cefuroxime, or erythromycin should be initiated, followed by oral administration. These antibiotics were found to be effective against the prevalent microbes associated with PPRM, suggesting their potential utility in managing this condition in resource-limited settings. This study provides valuable insights into the microbial profile and antibiotic susceptibility patterns in pregnant women with PPRM, offering guidance for clinicians in selecting appropriate antibiotic therapies tailored to the microbial profile observed in this population. Further research is warranted to validate these findings and optimize antibiotic treatment strategies for PPRM in diverse clinical settings.

Key words:- Preterm premature Membrane Rupture, Antibiotic Sensitivity Testing, Female genital tract, Microbiology, Preterm infants.

Access this article online

Home page:

<http://www.mcmed.us/journal/ajomr>

Quick Response code



Received: 25.10.19

Revised: 12.11.19

Accepted: 27.11.19

INTRODUCTION

Early premature rupture of membranes (PPROM) occurs before the 37 week mark of a pregnancy when the fetal membranes rupture before labor begins [1, 2]. In approximately one third of all preterm births, it occurs in 3% of pregnancies [3].

Corresponding Author

Anuradha V

The risk of PPRM to mother and fetus remains high despite advances in perinatal care [3–6]; there is an apparent link between PPRM and infections in the womb [7]. The use of antibiotics in PPRM is common, as antibiotics have been shown to prolong pregnancy and decrease neonatal morbidity. Ascending microbial agents are prevented from invading the uterus through the

administration of antibiotics. In order to determine the antimicrobial susceptibility pattern of the isolates, cultures of amniotic fluid a high vaginal swab as well as a low vaginal swab should be obtained. Interestingly, it is common for antibiotics to be prescribed without microbiological testing in resource-poor settings [11,12]. Consequently, antibiotic abuse is very likely, leading to serious health issues. The efficacy of broad-spectrum antibiotics examined none has been recommended. There is a common regimen for PPRM in the NICH trial. That regimen recommended intravenous ampicillin and erythromycin for 48 hours, followed by oral amoxicillin and enteric-coated erythromycin for 5 days [10, 13, 14]. In low-income countries, there has been no definitive recommendation concerning antibiotic treatment after PPRM. In resource-poor settings, PPRM poses a challenge in assessing antibiotic susceptibility. NICH does not recommend parenteral erythromycin for Nigerians. PPRM patients should not be treated with ampicillin due to prevailing antibiotic resistance. Pregnant women with and without PPRM were evaluated for their genital tract microbes, and their antibiotic susceptibility patterns were assessed. Healthcare institutions without laboratory facilities may recommend antibiotic treatment protocols based on the PPRM study conducted by the NICH.

METHODOLOGY

PPROM cases are often referred to the tertiary hospital. Women with PPRM who presented at Hospital's Labor and Delivery Unit were located on the second floor of the hospital between 28 and 37 weeks of pregnancy were classified as members of the PPRM group. Pregnant women in the non-PPROM comparison group were attending prenatal clinics without ruptured membranes. We matched a group of women with PPRM to a group of women without PPRM based on age, parity, and gestational age. In the PPRM group, women were excluded if they had PPRM before they presented, had previous digital examinations before they presented, received antibiotics within 7 days of presentation, or had active bleeding. A written informed consent was obtained from all participants and ethical approval was obtained from the Institutional Review Board. Samples were coded and numbered consecutively so that the microbiologist analyzing specimens had no idea which group they belonged to. Evaluation of rupture of membranes included a physical examination, history, and sterile speculum examination. Two of the following three clinical signs were present at the initial examination

for membrane rupture: pooling of fluid, nitrazine positive test, or microscopic evidence of ferning. Results were measured by detecting microorganisms and measuring antibiotic susceptibility.

The senior scientist of a medical laboratory will perform the analysis. Dry chocolate agar, blood agar, MacConkey agar, and Sabouraud dextrose agar were used. Incubation was done for 24–48 hours at 37 °C. After inoculation, each swab was placed onto a microscope slide, which was then examined under a microscope under the light of a microscope with saline added. Using Oxoid multi discs containing standard antibiotic concentrations, Kirby-Bauer disk diffusion was modified to test samples that developed cultures of microorganisms. As per the Clinical Laboratory Standards Institute [16], measured zone sizes and an interpretation were made based on the results. As part of a recent study, pregnant women in hospitals, *Gardnerella vaginalis* was reported to be 17% prevalent. To achieve 85% power to detect a difference between 3.5% and 17.0%, 91 participants per group were required. Epi Info and PASS version 12 were used for power analysis and sample size calculations. 105 women were enrolled in each group to account for loss to follow-up. For determining whether PPRM and non-PPROM bacterial species had any significant differences in prevalence, Epi Info version 3.5.1 and Stata version 10 were used [15].

RESULTS

There were 210 women in the study table 1 shows the demographic characteristics of the participants. Both groups appeared homogeneous ($P < 0.05$). It was found that the non-PPROM group had a mean age of 30.4 years, compared to 30.7 years for the PPRM group. Most women in the study had 0–2 children. Fertilization rate and gestational age were similar among PPRM and non-PPROM groups 31.4% x 1.8 weeks. A total of 166 (79.0%) of the samples collected from women with PPRM were bacterially contaminated (Table 2). *Staph.* PPRM participants were significantly more likely to identify these bacteria than non-PPROM participants (Table 2). The most effective antibiotic in the PPRM group was ampicillin-sulbactam: 162 (97.6%) of the 166 bacterial isolates were susceptible (Table 3). This group showed low levels of effectiveness for ampicillin, ampicillin-cloxacillin, and co-trimoxazole: only 42 isolates (25.3%), 50 (30.1%), and 50 (30.1%) were sensitive. Neither gentamicin nor ceftriaxone were effective against *Proteus mirabilis*. Non-PPROM isolates are shown in Table 4.

Table 1: The study population was characterized by the following socio demographic characteristics

Characteristics	PPROM (n = 210)	Non-PPROM (n = 210)	χ^2	P value
Age, (yrs)			0.00	1.000
16–20	10	12		
21–25	22	22		
26–30	62	64		

31-35	84	82		
36-40	26	26		
41-45	6	4		
Parity			0.03	0.863
0	44	42		
1	58	60		
2	56	54		
3	12	6		
4	28	30		
≥5	12	18		
Gestational age, wk			0.00	1.000
28-30	72	70		
31-33	36	46		
34-36	102	94		
Level of education			0.50	0.478
No formal education	4	0		
Primary education	6	2		
Secondary education	136	122		
Tertiary education	64	86		
Marital status			0.50	0.478
Single	4	0		
Married	206	210		

Table 2: Genital tract flora isolated from participating women.

Organisms	PPROM (n = 210)	Non-PPROM (n = 210)	P value
Streptococcus spp.	66	6	b0.001
Staphylococcus aureus	58	6	b0.001
Escherichia coli	20	2	0.005
Proteus mirabilis	10	0	0.070
Bacteroides spp.	8	0	0.130
Klebsiella pneumoniae	4	0	0.713
Negative specimens	44	196	b0.001
Total number of positive isolates	166	14	b0.001

Table 3: Isolated bacteria from the PPROM group are sensitive to antibiotics

Antibiotic	Streptococcus spp. (n = 66)	Staphylococcus aureus (n = 58)	Escherichia coli (n = 20)	Proteus mirabilis (n = 10)	Bacteroides spp. (n = 8)	Klebsiella pneumoniae (n = 4)
UNAS	66	58	18	10	6	4
STRP	64	56	16	8	6	2
GENT	62	54	14	2	8	4
CEFI	60	52	14	6	2	2
CEFU	60	50	16	8	4	0
CIPR	58	54	16	10	4	4
CEFT	56	52	10	2	2	2
ERYTH	54	50	8	6	2	2
CO-AM	44	28	4	4	2	2
LEVO	40	34	2	2	2	2
COTR	22	20	6	2	0	0
AMOX	22	10	6	2	2	0
AMPI	20	20	6	2	2	0

Table 4: Isolated bacteria in the non-PPROM group are more susceptible to antibiotics.

Antibiotic	Streptococcus spp. (n = 6)	Staphylococcus aureus (n = 6)	Escherichia coli (n = 4)

UNAS	6	6	2
STRP	6	6	0
CEFI	6	6	2
GENT	6	4	2
CEFU	6	4	0
CIPR	4	4	0
CEFT	4	4	0
ERYTH	4	2	0
CO-AM	2	2	0
LEVO	0	2	0
COTR	0	0	0
AMOX	0	0	0
AMPI	2	0	0

DISCUSSION

Insignificantly *Escherichia coli*, *Streptococcus* species, and *Staphylococcus aureus* were associated. As a result, this group of bacteria may cause PPRM directly or may serve as markers for another pathogen. A strong body of evidence suggests that antibiotics are useful in the treatment of PPRM in contrast to preterm labor. Prophylactic antibiotic treatment is rational since infections may cause as well as result from PPRM [16-18]. Preventing infections in mothers and fetuses and extending their latency periods are the goals of antibiotic therapy. The most useful antibacterial drugs used were ciprofloxacin, ceftriaxone, erythromycin, streptomycin, ampicillin-sulbactam, ciprofloxacin, gentamicin, cefixime, cefuroxime, and ciprofloxacin followed by cefixime, cefuroxime, and coamoxiclav and these agents were able to kill the bacteria. Comomoxiclav, on the other hand, can cause neonatal necrotizing enterocolitis. In addition, parenteral erythromycin is not available in Nigeria, nor does it treat anaerobes, Group B streptococcus, or bacterial vaginosis.

72 (86.7%) of the bacteria were successfully treated with gentamicin, supporting conclusions [19]. Gentamicin cannot be taken orally, and it potentiates ototoxicity and nephropathy. Hence, Gentamicin should only be used when alternatives are unavailable or streptomycin is contraindicated for congenital anomalies. Ciprofloxacin in pregnancy has not been tested for safety. It appears that therapeutic doses of medications during pregnancy pose little teratogenic risks when taken during pregnancy.

The least effective antibiotics were a combination of amoxicillin, ampicillin and cloxacillin, as well as co-trimoxazole: only 21–25 (25.3%–30.1%) of the isolates were sensitive. In PPRM, antibiotic regimens have been found to be useful [20,21], which is a concerning finding. The study area uses them frequently. The use of ampicillin-cloxacillin is often regarded as a drug that is habitually used for self-medication, which could explain why only 25 isolates (31.3%) tested positive for ampicillin-cloxacillin.

We were unable to test the sensitivity to metronidazole due to the antibiotic disc being

unavailable. PPRM is prevented in women with bacterial vaginosis by metronidazole, reports a study in the USA. Metronidazole is an antibiotic that is effective against a wide range of infections *G. vaginosis* and related bacteria.

There have been two large studies looking at the effectiveness of antibiotics for PPRM. In one of the groups enrolled as part of the study, intravenous antibiotics were given every 6 hours for 48 hours. An oral amoxicillin and erythromycin base combination was administered every 8 hours for a 7-day treatment. This study participants receiving antibiotic treatment had a shorter latency period. Antibiotic-treated women were twice as likely to remain undelivered. A prolonged latency lasted up to 3 weeks. Neonatally, antibiotic recipients had lower morbidity rates. Chorioamnionitis, necrotizing enterocolitis, and neonatal sepsis decreased. Co-amoxiclav alone or combined with erythromycin was used in the ORACLE trial [9]. Latency to delivery and neonatal morbidity did not differ significantly. In the USA, the antibiotic regimen is more commonly used for PPRM [13, 14]. In the case of patients with PPRM who are managed expectantly recommends 7 days of antibiotics.

There was sensitivity to ampicillin-sulbactam, cefixime, and cefuroxime in 81 and 69 cases, respectively. For the treatment of PPRM, it is recommended to use the following antibiotics in place of ampicillin, amoxicillin, and ampicillin-cloxacillin. Aside from this, there are many readily available antibiotics available, including ampicillin-sulbactam, cefixime, and cefuroxime. It has been recommended that 1.5g of ampicillin-sulfactam be administered intravenously every 12 hours in the present study, followed by 400mg cefixime, 250mg cefuroxime, 500mg erythromycin, or 375mg oral ampicillin-sulbactam is suggested, followed by 400mg cefixime, 250mg cefuroxime or 500mg erythromycin every 12 hours, followed by 500mg for a 7-day course of erythromycin, it is recommended that you take it every 8 hours. Penicillin allergies should be treated with cefixime or cefuroxime. In addition, the dosage of metronidazole is 500 mg every 8 hours for 48 hours, followed by 400 mg every 8 hours for 5 days

particularly in cases where anaerobe culture is difficult or G is detected by microscopy. The organisms are Gram-negative and anaerobic. Logistic difficulties prevented the isolation of bacteria from the genital tract, and metronidazole susceptibility testing was not conducted because antibiotic discs were unavailable. Moreover, the minimum fetal viability age was 28 weeks of pregnancy. The findings of this study suggest that early detection of lower genital tract infections and aggressive treatment may improve the outcome of PPRM in women who are at risk of developing it.

Conclusion

A complete understanding of fetal membrane processes requires more research. For the conservative treatment of PPRM, cefixime, cefuroxime, ceftriaxone, and ampicillin-sulbactam. However, erythromycin cannot be taken in parenteral form and ceftriaxone cannot be taken orally. It recommends combining these antibiotics with metronidazole intravenously for 48 hours, followed by oral administration for 7 days. In some cases, it may be useful when there is an inadequate PPRM facilities or while waiting for culture and sensitivity results. To prevent antimicrobial resistance and antibiotic abuse, it is imperative that these findings are reviewed on a periodic basis.

REFERENCES:

1. Orhue AAE. (2006). Preterm Labour and Premature Rupture of Membranes. In: Agboola A, editor. Textbook of Obstetrics and Gynaecology for Medical Students. 2nd ed. Ibadan: Heinemann Educational Books Nigeria, 423–9.
2. Odunsi A, Odutayo R. (2003). Premature Rupture of Fetal Membranes. In: Okonofua F, Odunsi K, editors. Contemporary Obstetrics and Gynaecology for Developing Countries. Benin City: Women's Health and Action Research Centre, 430–53.
3. Obi SN, Ozumba BC. (2007). Pre-term premature rupture of fetal membranes: the dilemma of management in a developing nation. *J Obstet Gynaecol*, 27(1), 37–40.
4. Hosseini MA, Nahidi F, Majdfar Z. (2007). Comparison of fern and evaporation tests for detection of ruptured fetal membranes. *East Mediterr Health J*, 13(1), 197–200.
5. Liu J, Feng ZC, Wu J. (2010). The incidence rate of premature rupture of membranes and its influence on fetal-neonatal health: a report from mainland China. *J Trop Pediatr*, 56(1), 36–42.
6. Etuk SJ, Etuk IS, Oyo-Ita AE. (2005). Factors influencing the incidence of pre-term birth in Calabar, Nigeria. *Niger J Physiol Sci*, 20(1–2), 63–8.
7. Aboyeji AP, Abdul IF, Ijaiya MA, Nwabuisi C, Ologe MO. (2005). The bacteriology of pre-labour rupture of membranes in a Nigerian teaching hospital. *J Obstet Gynaecol*, 25(8), 761–4.
8. Kenyon S, Boulvain M, Neilson J. (2003). Antibiotics for preterm rupture of membranes. *Cochrane Database Syst Rev*, 2, CD001058.
9. Kenyon SL, Taylor DJ, Tarnow-Mordi W. (2001). ORACLE Collaborative Group. Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group. *Lancet*, 357(9261), 979–88.
10. Mercer BM, Miodovnik M, Thurnau GR, Goldenberg RL, Das AF, Ramsey RD. (1997). Antibiotic therapy for reduction of infant morbidity after preterm premature rupture of the membranes. A randomized controlled trial. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. *JAMA*, 278(12), 989–95.
11. Caughey AB, Robinson JN, Norwitz ER. (2008). Contemporary diagnosis and management of preterm premature rupture of membranes. *Rev Obstet Gynecol*, 1(1), 11–22.
12. Hart CA, Kariuki S. (1998). Antimicrobial resistance in developing countries. *BMJ*, 317(7159), 647–50.
13. ACOG Committee on Practice Bulletins-Obstetrics. (2007). ACOG Practice Bulletin No. 80: premature rupture of membranes. Clinical management guidelines for obstetrician-gynecologists. *Obstet Gynecol*, 109(4), 1007–19.
14. American College of Obstetricians and Gynecologists. (2002). ACOG Committee Opinion: number 279, December 2002. Prevention of early-onset group B streptococcal disease in newborns. *Obstet Gynecol*, 100(6), 1405–12.
15. Cousins LM, Smok DP, Lovett SM, Poeltler DM. (2005). AmniSure placental alpha microglobulin-1 rapid immunoassay versus standard diagnostic methods for detection of rupture of membranes. *Am J Perinatol*, 22(6), 317–20.
16. Clinical and Laboratory Standards Institute. (2014). Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. www.microbiolab-bg.com/CLSI.pdf. Published January 2007. Accessed May 27.
17. Adinma JIB, Okwoli NR, Agbai A, Unaeze N. (2001). Prevalence of *Gardnerella vaginalis* in pregnant Nigerian women. *Afr J Reprod Health*, 5(1), 50–5.
18. Lewis DF, Fontenot MT, Brooks GG, Wise R, Perkins MB, Heymann AR. (1995). Latency period after preterm premature rupture of membranes: a comparison of ampicillin with and without sulbactam. *Obstet Gynecol*, 86(3), 392–5.

19. Therapeutic Goods Administration, Australian Drug Evaluation Committee. (2014). Prescribing Medicines in Pregnancy: An Australian Categorisation of Risk of Drug Use in Pregnancy. 4th edition. <http://www.huidziekten.nl/richtlijnen/medpreg.pdf>. Published 1999.
20. Friedman JM, Polifka JE. (2000). Teratogenic effects of drugs: a resource for clinicians (*TERIS*). Baltimore: The Johns Hopkins University Press.
21. Yah SC, Yusuf OE, Eghafona NO. (2008). Pattern of antibiotic usage by adult populations in the city of Benin, Nigeria. *Sci Res Essays*, 3(3), 81–5.

Cite this article:

V. Anuradha. Microbial Profile And Antibiotic Sensitivity In Preterm Premature Rupture Of Membranes (PPROM) Among Pregnant Women: Implications For Treatment In Resource-Limited Settings. *American Journal of Oral Medicine and Radiology*, 2019, 6(2), 69-74.



Attribution-NonCommercial-NoDerivatives 4.0 International